Tissue Anirgens 1994. 44: 1-18 printed in Denmark ,4li ri&s rcserved

C o p y r r g h / 0 Munksgaard 1994

T I S S U E A N T I G E N S [SSN 0001-28l5

Nomenclature for factors of the HLA system, 1994 1. G. Bodmer, S. G. E. Marsh, E. D. Albert, W. F. Bodmer, B. Dupont, H. A. Erlich, B. Mach, W. R. Mayr, P. Parham, T. Sasazuki, G. M. Th. Schreuder, J. L. Strominger, A. Svejgaard, P. I. Terasaki. Nomenclature for factors of the HLA system, 1994. Tissue Antigens 1994: 44: 1-18. 0 Munksgaard, 1994

The WHO Nomenclature Committee for factors of the HLA system met in Strasbourg in March 1994 at the European Foundation for Immunogen- etics Conference to consider additions and re- visions to the nomenclature of specificities defined by both molecular and serological techniques fol- lowing the principles established in previous re- ports (1, 3, 3, 4, 5 , 6, 7, 8, 9, 10, 11).

The main subjects discussed were:

1. Naming of new HLA genes 2. Naming of new alleles 3. Naming of alleles of other genes in the HLA

4. Promoter region variants 5. Naming of null alleles 6. Naming of specificities identified by low resol-

ution DNA typing 7. The HLA sequence databank 8. The HLA sequenced cell bank 9. Publication of new sequences

region

1. Naming of new HLA genes

Two new HLA genes, HLA-K and HLA-L, were named as shown in Table 1, both of which are novel Class I pseudogenes located near HLA-A.

Julia G. Bodmer, Steven G.E. Marsh, Ekkehard D. Albert, Walter F. Bodmer, Bo Dupont, Henry A. Erlich, Bernard Mach, Wolfgang R. Mayr, Peter Parham, Takehiko Sasazuki, Geziena M. Th. Schreuder, Jack 1. Strominger, Arne Svejgaard and Paul 1. Terasaki

Received and accepted for publication 20 May 1994

2. Naming of new alleles a. Conditions for acceptance of new allele sequences

As emphasized in previous reports there are re- quired conditions for acceptance of new sequences for official names.

1. Several clones should have been sequenced. 2. Sequencing should have been performed in both

directions. 3. An accession number in a databank should have

been obtained. 4. Full length sequences are preferable though not

essential. 5. Where possible a paper should have been sub-

mitted for publication. 6. DNA or other material, in particular cell lines,

should be made available in a publicly accessible repository or at least in the originating labora- tory. Documentation on this will be maintained by the Nomenclature Committee.

It should be noted with some caution that cells from which only partial sequences have been ob- tained may later be shown to represent different or novel alleles when further sequencing is performed. This is of particular importance in cases where

1

Bodrner et al.

Table 1 Names for genes in the HLA region

~

Previous References for Namea equivalents Molecular characteristics new genes

HLA-A HLA-B HLA-C HLA-E HLA-F HLA-G HLA-H HLA-J HLA-K HLA-1 HIA-DRA HLA-ORB1 HLA-DRB2 HLA-DRB3 HLA-ORB4 HLA-ORB5 HLA-ORB6 HLA-DRB7 HLA-ORB8 HLA-ORB9 HLA-DQA1 HLA-ORB1 HLA-DQA:! HLA-DRB2 HLA-ORB3 HLA-DOE HLA-DMA HLA-DMB HLA-DNA HLA-DPAl HLA-OPE1 HLA-OPA2 HLA-OPE2

TAP1 TAP:! LMP2 LMP7

- - - E. ‘6.2’ F, ‘5.4 G, ‘6.0’ H, AR, ‘12.4 cdal2 HLA-70 HLA-92 DRa DRPI, DR1B DRPll DRPIII, DR3B DRPIY DR4B ORPIll DRBX, DRBo DRBvI DRBv2 M4.2 p exon m a i , oai A oapi, oai B DXa. DQ2A oxp, o a 2 ~ DVP, DQB3 OOP RING6 RING7 DZa, DOU

DPal, DPlA DPP1, DP1B DPa2, DP2A DPp2, OP2B

RING4, Y3, PSFl RING11, Y1, PSF2 RING1 2 RING10

Class I a-chain Class I ctchain Class I ctchain associated with class I 6.2-kB Hind 111 fragment associated with class I 5.4-kB Hind 111 fragnjent associated with class I 6.0-kB Hind 111 fragment Class I pseudogene associated with 5.4-kB Hind 111 fragment Class I pseudogene associated with 5.9-kB Hind Ill fragment Class I pseudogene associated with 7.0-kB Hind Ill fragment Class I pseudogene associated with 9.2-kB Hind Ill fragment DR a chain OR p1 chain determining specificities DR1, OR2, OR3, OR4, OR5 etc. pseudogene with OR p-like sequences OR p 3 chain determining OR52 and Dw24, Dw25, Ow26 specificities OR p 4 chain determining OR53 OR p 5 chain determining OR51 DRB pseudogene found on DR1, OR2 and OR10 haplotypes. ORB pseudogene found on DR4, OR7 and OR9 haplotypes. DRB pseudogene found on DR4, OR7 and OR9 haplotypes. ORB pseudogene, isolated fragment DQ a chain as expressed DR p chain as expressed DQ a-chain-related sequence, not known to be expressed DO P-chain-related sequence, not known to be expressed DR P-chain-related sequence, not known to be expressed DO p chain DM a chain OM p chain ON a chain DP CL chain as expressed DP p chain as expressed DP a-chain-related pseudogene DP P-chain-related pseudogene

ABC (ATP Binding Cassette) transporter ABC (ATP Binding Cassette) transporter Proteasome-related sequence Proteasomerelated sequence

aGene names given in bold type have been assigned since the 1991 Nomenclature report.

several different cells have been partially sequenced for an allele and all have been listed in this report.

Official designations are currently being assigned to new HLA alleles in the intervening period be- tween Nomenclature Committee meetings, provid- ing they meet the criteria outlined above. The listing of references to new sequences does not imply priority of publication. The use of numbers or names for alleles, genes or specificities which pre-empt formal designations such as “HLA-M”, “A*0103”, “DRBI *O 105”, or “HLA-DL” before consideration by the Nomenclature Committee is strongly discouraged.

b. New allele names

In the Class I region; nine HLA-A, 37 HLA-B, 16 HLA-C and four HLA-G alleles were named as

shown in Tables 2, 3, and 4. The designation B*39012 has been omitted from Table 3, as the sequence of the cell line originally thought to have this sequence was later found to be identical to the corrected B*39011. Since the previous report further sequencing information has revealed the sequence originally named as B*790 1, originally published as a B-locus blank, to be more closely related to members of the B70 family and this allele has now been renamed B* 15 18 in accordance with the naming of other B70 sequences (32, 29).

The sequence originally designated B*440 1 has now been found to contain errors and be identical to the corrected sequence for B*4402, (E. Pet- ersdorf personal communication) (48,49). Accord- ingly the name B*4401 has now been officially dropped.

In the Class I1 region; 47 DRBl alleles, three

2

Nomenclature for factors of the HLA system, 1994

Table 2 Designations of HLA-A alleles

HLA HLA Previous Individual or Cell Line from Accession References or Allelesa Specificity Equivalents which the sequence was derived Number Submitting author(s)

KO101 A1 A'0102 A1 KO201 A2 A'0202 A2 A'0203 A203 KO204 A2 A'0205 A2 KO206 A2 A'0207 A2 A'0208 A2 KO209 A2 KO210 A210 KO211 A2 A'0212 A2 A'0213 A2 A'0301 A3 A'0302 A3 A'1101 A l l A'1102 A l l A'2301 A23(9) A'2401 A24(9) A'2402 A24(9) A'2403 A2403 A'2501 A25(10) A'2601 A26(10) A'2602 A26(10) A'2603 A26(10) A'2604 A26(10) A'2901 A29(19) A'2902 A29(19) A'3001 A30(19) A'3002 A30( 19) A'3003 A30(19) A'31011 A31(19) A'31012 A31(19) A'3201 A32(19) A'3301 A331 19) A'3302 A33( 19) A'3401 A34(10) A'3402 A34(10) A'3601 A36 A'4301 A43 A'6601 A66( 10) A'6602 A66(10) A'6801lC A68(28) A'68012 A68(28) A'6802 A68(28) A'6901 A69(28) A'7401 A741 19) A'8001 -

- - A2.1 A2.2F A2.3

A2.2Y A2.4a A2.4b A2.4~

-

AZ-OZB A2-LEE A25

AZSLU A3.1 A32 Al lE, A1l . l A l l K , A11.2

-

- - - A9.3

A26.1 A26.3 A26.2, A26.1 A26.4 A1 OSA

A292 A30.3, A30RSH A302 A30JS

-

-

- - - Aw33.1 Aw33.2 - - - - - - Aw68.1 Aw68.1 Aw68.2 - - AX"BG", A-new

LCL721~ MOLT4 DAUDI

M7 OK1 RML, AN WT49, AM CLA, T7527 KNE KLO OZB

KIME, GRCI38 KRC033 SLUGEO JG El 82

K.LIE, KOK. CTA SHJO, EL.ON JG SHJO, 32/37, KRC032 APA, KPE BM92 GM637. 02BN5. MGAR. N.M. KT14. Y.I., E.K. T.M.. S.M. Y.S. JOE LAM LBF, RSH CR-B JS, HT JHAF KRC033, TB AM JOE IT ENA WWAl MASCH cc 2511 506, TEM CR-B, MALS, HUT 102 LB GRCl87 PA, TO IDF, ZM, BJ CC, PDAY ATUR VH, 35020, 35841, 32511, CODI, MIKA, LADA

LCL721, JY, GM637, GRCl38, T5-1

XLI-ND

CJO-A, K.LIE, MMU, YMU

X55710, M24043 U07161 M32322, K02883, M84379, X02457 M17566. M17568 U03862, M17567, M19670 X57954, M86404 U03863 M24042 - - - 223071 X60764. M84377 M84378 2271 20 X00492, KO2057

M16007, M16008, X13111, D16841 X13112, 016642 M64742 M15497 M64740, M84376 M64741 M32321 M24095. U03697, Dl 6843 M98453, D14350 01 4351 01 4354 M23739 X60108 M30576. M28414, U07234 X61702 M93657 M30578. M28416 M84375, M86405 P10314 M30580, M28415 LO6440 X61704 X61705 X61700 X61703 X61711 X61712, X51745 X03070, X03071 LO6425 U03861 X03158. X03159 X61701 M94880, L18898, L19403

-

a Allele names given in bold type have been assigned since the 1991 Nomenclature report.

* This reference is to a corrected sequence.

This reference is to a confirmatory sequence. This sequence has been previously assigned with a four digit allele name.

DRB4, one DRBS and two DRB7 alleles were The sequence originally designated DRBI *0703- named (see Table 5) , one DQAl and seven DQBl has now been shown to have been in error and to alleles were named (see Table 6)- 21 DPBl alleles be identical to DRBl*070l ( 1 17), accordingly the were named (see Table 7) and four DMA and four name DRB I *0702 has been officially dropped. DMB alleles were named (see Table 5). Two DPBl sequences which were originally as-

3

Bodmer et al.

Table 3 Designations of HLA-B alleles

HLA HLA Previous Individual or Cell Line from Accession Allelesa Specificity Equivalents which the sequence was derived Number

References or Submitting author@)

8'0701 8'0702 8'0703 B'0704 8'0801 8'0802 8'1301 07302 8'1 401 8'1402 8'1501 8'1502 8'1503 8'1504 8'1 505 8'1506 8'1 507 8'1508 8'1509 8'1510 8'151 1 8'1512 8'1513 8'1514 8'1515 8'1516 8'1517 8'1518 8'1519 8'1520 8'1 801 BY802 8*2701 8'2702 8'2703 8'2704 8'27O5lc 8'27052 8'2706 8^2707 8'2708 8'3501 8'3502 8'3503 8'3504 8'3505 8'3506 8'3507 8'3508 8'3701 8'3801 8'3802 8'3901 1' 8'39013 8'39021': 8'39022 8'3903 8'3904 8'4001 1':

87 87 8703 87 B8 88 81 3 81 3 864( 14) 865(14) 862(15) 875(15) 872(70) 862(15) B62(15) B62(15) 862(15) 862(15) 870 871 (70) 81 5 876(15) 877(15) 876(15) 862(15) 863(15) 863( 15)

876(15) B62(15) 81 8 818 027 827 827 827 827 827 827 827

835 835 835 835 835 835 835 835 837 838(16) 838(16) 83901 83901 83902 83902 839(16) B39( 16) B60(40)

-

-

87.1 87.2 BPOT B7E

B8V 81 3.1 81 3.2

-

- - - - - 8~62-G Bw62.1 8w62.4 Bw62.5 662variant 870.1 870.2 81 5variant 876 877 876 862s 863.1, 8W66 863

876 8'7901, BX-HS

- - 81 8PE 27f 27e, 27K, 827.2 27d, 27J 27b. 27C, 827.3 27a, 2 7 4 827.1 27a, 27W, 827.1 274 827.4

870ui 827-HS

- - - - 835-6 835-K - B35TL

81 6.1

839.1, 816.2 839.1 J 839.2 839.2

839N

-

- -

CF JY POT71 10243 LCL721, MF, CGMI 2001 5 HE LBF, TO MAW, 32367, W6106 BE, CGMl ME HA, BCK, OLGA (OLL)d, KT17 APA, LW CC, 26931, 31 708 GRC138, KG VB WI SB KHAGNI, LATIF, OAN723 34863 2551 4, 1901 4, (311373 LEE743 THAI742

SS713 MLH727

RSA-NO, CAM020

DOP-ND, 21909, 31133 JAP-NF HS GEE01 8 OLGA (OLL)d SGAR, F24 PETCH LH BRUG CH WEWAK 1 BRUG CD, HC, MRWC, KCA, MVL, LG2 LIE, PAR HS 19418, BCK HS, KT17 OL C1R. HMY2 AN GRC212, KRC032 KRC103 #2073 #22338, TL KASO11, MG 2 RSA-ND S, JC IT #591 YAM CL170 AUCA#19 TO LB. #W7079

- M16102, M32317, M35444, PO1 889 X64454 U04245 M59841, M24036, M28204 U04244 M24075 M19757, M24041 M24040 M59840, M24032 M28203, M83193, U03859 M75138, M83192 X61709 M84382, M86402 M83191 ME31 94 M83195 L11666 L11571 L11570 L11604 L11603 L15005 L19937 L22027 LO9735 U01848

U03027 U06862 M24039 D25275

X03664, X03667 M54883, M37272

X03665, X03666 X03945, M12967, L20086, M14013, M12678 X73578 M62852 L19923

M63454 ME1 798 M86403 ME4385 M84381 LO4695 L04696, 222651 M32320 M29864 L22028 M94052, M29865 M94051 M94053 U04243 L20088 L22649 PO1 890, U03698

-

-

-

M28109-12

4

Nomenclature for factors of the HLA system, 1994

Table 3 Continued -

HLA H LA Previous Individual or Cell Line from Accession Allelesa Specificity Equivalents which the sequence was derived Number

References or Submitting author@)

8'40012 860(40) B'4002 B61(40) 8'4003 840 8'4004 840 8'4005 84005 8'4006 861(40) 8'4101 841 8'4201 842 8'4402 844(12) B'4403 B44(12) 8'4404 B44(12) 8'4501 B45(12) 8'4601 846 8'4701 847 8'4801 848 8'4802 848 8'4901 B49(21) 8'5001 850(21) 8'5101 851(5) 8'5102 85102 8'5!03 85103 8'5104 851(5) 8'51 05 851 (5) B'52011d 852(5) 8'52012 852(5) 8'5301 853 8'5401 854(22) 8'5501 855(22) 8'5502 855(22) 8'5601 B56(22) 8'5602 656(22) 8'5701 657(17) 8'5702 857(17) 8'5801 658(17) 8'5901 859 8'6701 667 8'7301 673 B'7801 87801

B6OUt 840' B40-G1 B40-G2 BN21 861 - - 844.1, 844.2 844.1:New 844.4

- 85.35 BTA

851 v -

-

- B'SNA'.Bxl

Ut-rn SWEIG, CALOGERO. YUKI, 1901 4 GRCl38 GRC212 001 36 Ot-s SGAR 88 FMB. BAU PITOUT, F24 TAN, BE8 OMW T7527, THAI742 PLH KRC103, HS67 AUCA#18 AM SH.JO

UM. 02627

KRCOO5, GRC187, GRC150 LK MT, LK707 AUCA#2 AMAI, AM

VEN APA voo ENA WIN, MOC, MOLT4 32/32 wr49 AT, KY HS67,#591, #W7079 LK707, LE023, HL SNA, 32/32

LKT-2, TO, BM92, CD

30-BY3

LKT-3, TTL

M95530 L09736, D l 4343 M84383 M84384 M84694 M95531 M24035 M24034 M24038, M15470 X64366 X75953, X78426, X78427 X61710 M24033 M19756 M84380 L20089 M24037 X61706

M68964 M80670 21 51 43 U06697

L20090 M33574. M58636 M77774 M77778 M77777 M77776 M77775 X55711, M32318 X61707 M11799 LO7743 L17005 U04787, X77658, L24373' X61708, M33573

M32319, M21035, M22786-8, M28207

M21036, M22793-9

(46) Tokunaga (47, 30)b

E. Petersdorf, (48, 49)e P. Parham (50, 49)

( ~ 9 ) ~

(42Y (37)

(55) (42) (54, 56), L. Lamm

a Allele names given in bold type have been assigned since the 1991 Nomenclature report. This reference is to a confirmatory sequence. This sequence has been previously assigned with a four digit allele name. Cell line is also known by alternative name. This reference is to a corrected sequence.

signed as DPB1*4201 and DPB1*4301 are not in- cluded in Table 7, as they have been retracted and shown to be identical to previously named sequences.

3. Naming of alleles of other genes in the HLA region

A total of five TAP1 and three TAP2 alleles were named (see Table 9) in accordance with previous committee policy.

4. Promoter sequences In the discussion on quences two possible

the naming of promoter se- approaches were discussed.

1. That the promoter sequence is an integral part of the allele as for instance any other exon or epitope of an allele sequence.

In this case every promoter sequence associ- ated with an allele will be identified by the letter P following the allele name with 01, 02 etc. i.e. DQA1*0101P01, DQAl"0101P02 etc. In this case PO1 and PO2 refer to the promoter sequence identified in the DQA1*0101 allele only.

Or

2. That promoter sequences should be named as separate entities.

Thus the names POI, PO2 etc. would be ap- plied to a given promoter sequence regardless of which allele i t is associated with.

5

Bodmer et al.

Table 4 Designations of HLA-C. -E, -G alleles

HLA HLA Previous Individual or Cell Line from Accession Allelesa Specificity Equivalents which the sequence was derived Number

References or Submitting author(s)

cw*o101 Cwl Cw*Ol02 Cwl cw*0201 cw2 ck02021 cw2 Cw'O2022 cw2 Cw'O301 Cw3 Cw'0302 Cw3 Cw'0303 Cw3 hW'0304 Cw3 Cw'O401 Cw4 Cw'0402 Cw4 Cw*0501 Cw5 Cw'0601 Cw6 Cw'0602 Cw6 Cw'0701 Cw7 Cw'0702 Cw7 Cw'0703 Cw7 Cw'O801 CW8 Cw'O802 CW8 Cw'0803 Cw8 Cw'l201 - CW'1202lC - cw.12022 - Cw'1203 - Cw'l301 - Cw'l401 - Cw'1402 - W 1 5 0 1 - Cw.1502 - CW'1503 - CW'1504 - CW'1601 - G ~ * l 6 0 2 - CW'1701 - E'0101 - E'0102 - E'0103 - E'0104 - G'01011 - 6'01012 - 6'0102 - 6'0103 -

Cwl.1 cw1.2 cw2.1 cw2.2 cw2.2 - - - - - BeWo C.1 - - Cw6(W)

JY328 -

HLA-4 - - - Cx52 Cb-2 Cw'1202gyp Cwl2New CWBLl8 Cb-1 Cwl4New c1.9 C'X, Cw'6.2 - Cw'l5Sp CI.10 Cw'l6v Cwl 6New JTWl5

M32507 M32508

BeW 67 Ice 6.23-5.4H G'III

HLA-6.2

HLA-6.0, G'I

BRUG T7527, AP BRUG MVL SWElG JG AP GRCl50 KRCl 10 C1 R, KRClO3 BeWo

JOE MS, 6088, DJS MF JY ? 02627 CGMl , LWAGS, WT51 KRClO3 AKlBA MT GO85 0020891 5, WDV YAR TCC LKT2 LU Y GM637 AUCA#2,6085, GO88 GRC150 C047 GM637 C073 RSH JT, YN, HF LCL721 MT, MH, TK KS LCL721.144. ASR53, MOU, SP0010 BeWo ICE 6 LWAGS

m, RC

M16272 M84171 M16273 M24030 M26712 K02058, X00495 M84172 M99390 M99389 M84386, X58536 M26432 M58630. M34290, L24491 M28160

M28205

M11886 M84174

Z15144

M28172. M28174. M28176. M28178 X70856 U06695, U06696 M58631, M34291 M28171, M28173, M28175, M28177 U06487 M24096 L20091, X67818 M99388 X73518 M24097 X76189 U06835 M20022 M21533 M32507 M32508 J03027. X17273, L2f836, L27837 M32800 569897 M99048

M28206. X70857, 222752-4

-

~ 5 9 8 6 5 , ~ 8 4 1 7 3

M21963, D12471-2

a Allele names given in bold type have been assigned since the 1991 Nomenclature report. has been previously assigned with a four digit allele name. This reference is to a corrected sequence.

This reference is to a confirmatory sequence. This sequence

While it initially seemed possible to follow the sec- ond strategy of giving a promoter sequence a name regardless of which allele it was associated with, problems of the length of the region to be se- quenced and possible variations in unsequenced parts led to the decision to postpone the naming of promoter sequences until the results of dis- cussions in the HUGO Nomenclature committee on related topics are known, later this year. Mean- while a temporary nomenclature based on that used in the 1 1 th workshop ( 1 79) i.e. QAP* 1.1 will be used.

5. Naming of DRB4 null allele in OR7 Dwll haplotypes

It was agreed that the letter 'N' for null would be entered in the final field of non-expressed alleles.

N is defined as indicating a sequence defect in an HLA allele or gene which prevents normal ex- pression of the product at the cell surface (it does not necessarily imply that no internal partial prod- uct is made which might be a T-cell target).

Thus the DRB4 null allele on the DR7 Dwll haplotype carrying a mutation near a splice site will be named as DRB4*01012N to distinguish it

6

Nomenclature for factors of the HLA system, 1994

Committee. There will be no charge for this service to the submitting laboratory.

from the normally expressed DRB4*O 101 which will now be known as DRB4*01011 (see Table 5) . DRB4*01012N should only be assigned when the specific mutation site has been tested.

6. Naming of specificities identified by low-resolution DNA typing

Much DNA typing is, initially at least, carried out only at low resolution with the result that it is not possible to identify which of many alleles of a specificity such as DR4 are present. With many specificities it is possible to abbreviate, for example DRBl*O3, DRB1*04 etc., by truncating the more specific allele name. In the case of variants of DR2 and DR6, however, this has not been possible since DRB 1*02 and DRB 1 *06 were not used in the nam- ing of the DR2 and DR6 related alleles.

As a matter of convenience it has therefore been agreed that this nomenclature, DRB1*02 and DRB1*06, should be allowed for the results of low-resolution typing. It was further agreed that a subcommittee of the Nomenclature committee, possibly with other co-opted members, will work out more extensive guidelines for the naming of the results of low-resolution DNA typing.

7. The HLA sequence databank

Since the advent of DNA typing, HLA nomencla- ture depends heavily on the maintenance of a se- quence bank in which newly submitted sequences can be checked against existing sequences and all sequences can be made available to workers in the field. The HLA sequence databank is currently maintained at the I.C.R.F. in London by S. Marsh, with P. Parham, Stanford collecting and checking the Class I sequences provided to the London bank.

8. The HLA sequenced cell bank

A bank of all available sequenced cell lines is being set up at the European Collection of Animal Cell Cultures (ECACC), Porton Down, UK as part of the studies for the Twelfth International Histocom- patibility Workshop. These will be available to all those interested. Laboratories identifying new HLA alleles by sequence are urged to send either lymphoblastoid cell lines or, preferably, viable cells for transformation to the ECACC, once they have registered their sequence with the Nomenclature

9. Publication of new sequences

In response to the need to make information avail- able on a rapid basis it has been decided to publish a listing of references to newly assigned sequences in Tissue Antigens on a monthly basis.

Acknowledgments

The scientific contribution of Prof. Dominique Charron, who acted as a co-opted member of the committee is gratefully acknowledsed. The meeting was partially supported by financial contributions from Biotest and Dynal.

List of committee members involved in preparing this report:

J. G. Boa'mer, Imperial Cancer Research Fund, London, UK (Rapporteur) E. D. AIbert, Policlinic for Children, University of Munich, Germany, (Chairman) W E Boa'mer, Imperial Cancer Research Fund, London, UK B. Dzcpont, Sloan-Kettering Institute for Cancer Research, New York, N.Y., USA H. A . Erlich, Cetus Corporation, Emeryville, Ca., USA B. Mach, University of Geneva, Geneva, Switzer- land S. G. E. Marsh, Imperial Cancer Research Fund, London, UK W R. M a y , University of Vienna, Vienna, Austria f? Parham, Stanford University School of Medi- cine, Stanford, Ca., USA T Sasasuki, Kyushu University, Fukuoka, Japan G. M. Th. Schreuder, University Hospital, Leiden, The Netherlands J. L. Strorninger, Harvard University, Cambridge, Ma., USA A. Svejgaard, State University Hospital, Copen- hagen, Denmark P I. Terasaki, University of California, Los Ange- les, Ca., USA

Co-opted member:

D. C. Charrun, Institut BiomCdical des Cordeliers, Paris, France.

7

Bodmer et al.

Table 5 Designations of HLA-DR alleles

HLA Serological (T-celCdefined) Previous from which Accession Submitting Allelesa Specificities Specificities Equivalents the sequences was derived Number author(s)

HLA-DR HLA-D-associated Individual or Cell Line References or

DRA'0101 DRA'OlO2 DRB1'0101 DRBI '01 02 DRBI-0103

ORBl *0104 DRBl'1501 ORBl *15O2lC ORB1'15022 DRBl'1503 ORB1'1504 DRB1'1601 ORB1 '1 602 ORB1'1803 ORBl 'I 804 ORBl '1605 ORB1'1806 ORB1 '0301 1'

DRB1'03012 DRB1.0302 DRB1'0303 ORB1'0304 DRB1'0401

DRB1*0402 DRB1'0403 DRB1.0404 DRB1'0405 DRB1'0406 DRBl'D407 DRB1'0408

DRB1'0409 DRB1'0410 DRB1'0411 DRB1.0412 DRBl'O413 ORB1'0414 ORB1'0415 ORB1 '04 16 ORBl'O417 ORB 1 '04 1 8 ORB1'0419 DRB1'11011 DRBI'I 101 2 DRBl'IlOP DRB1'1103 DRB1'11041 DRBl'11042 DRB1*1105 ORB1'1108 ORB1 '1 107 DRBl'1108 1 ORB1'11082 ORB1'1109 ORB1'1110 ORB1'1111

ORB1'1112 ORB1'1113

DRBI '1 201 DRB1'1202 ORB1'1203 DRB1.1301 DRB1'1302 DRBl'1303

DRB1'1304 DRBl'1305 DRBl.1306

- - DR1 DR1 DRlO3

DR1 DR15(2) DR15(2) DR15(2) DR15(2) DR15(2) DR16(2) DR16(2)

DRl6(2)

DR2 DR17(3)

DR17(3) DR18(3) DR18(3) DR3 OR4

DR4 OR4 DR4 DR4 DR4 DR4 DR4

OR4 DR4 OR4 DR4 DR4 DR4 DR4 OR4 DR4 DR4 DR4 DRl l(5) DR1 l(5) DRII(5) DRII(5) DRll(5) ORll(5) DR1 l(5) DRll(5)

DRIl(5) DR1 l (5) DR1 l(5)

- -

-

- - - -

DR12(5) DRIZ(5) DR12(5) DR13(6) DR13(6) DR13(6)

DR13(6) DR13(6) DR13(6)

- - Dwl Ow20 Dw'EON

Dw2 Dwl2 Dwl2

Dw21 Dw22

-

- -

- - - - Dw3

Ow3 Dw'RSH'

Dw4

Dwl 0 Dw13 Dwl4 Ow15 Dw'KT2' Ow13 Dw14

- -

- - - - - - - - - - - Dw5 Dw5 Dw'JVM

Dw'FS' -

- - - - - - - - -

-

Dw'DB6'

Owl 8 Dw19 Dw'HAG

- -

- - -

ORctPDR-ct-2 DR-H

DRI -NASC DRl-CETUS,

-

DRBl'BON DRBl'OINew DR2B Dw2 DR2B Dw12 DRZMll

DRZDAl DRZB Dw21 DRZB Dw22

DRB1'16x8

-

- - 1 6PRET - DRBI'IMR - - 03MIT -

- OR4 Owl3A. 13.1 DR4 Dwl4A, 14.1

DR4 Dwl38, 13.2 DR46ETUS, Dwl4B,14.2

DR4.CB DR4.EC AB2 DRBI'LEV DR4 Dw10.2

- -

-

- DR4-BELF DRB1'04SAM DRBI '04.N DR4FK DRwl 1.1

ORwll.2 DRwl1.3

-

- - - DRl l .CCY 11 PMH

DRI 1 JL DR11 HW DRBI'MON DR11.5 DR11.6. D R l l BRA

D R I 1.7

-

OR1 1-1 4

- DRwl 2b DRwlZPOPE DRw6a I DRw6c I -

RE1 125-1 4 DRwG'PEV DRBlV3.MW

JY, RAJI, F.G JY i5.1, LG2 NASC. 1568 RAI, BG, BON

LA.

BGE. DHO CMURO 6247 D13, 053

REM (RML)* JWR BONA, FORE EH.B. PRET4149 RAJI. AVL WT49, OM24, DM28, DM29, CMCC 21. M.R. 2041, 1563 RBL 825 MIT3758 W51, PRESS, MJ4. BDLFlH

PGF, ROF-NL

AZH. MN-2

FS. DM24. MMCC SSTO, TAS BIN40, LS40. DM29 KT3. JML. AHC. CRP KT2 JHF, R88 M36, RA1

R80 CE, ABCC60 EC. HV846 ABO1078 LEV VK NIC, HOU BEL5GB

A17, A18 FK SWEIG 1180, 1249 JVM

FPA (FPF)d 2094 DBUG CCY, PMH161 BEL6KG

TOE-0070

UA-SZ

JL HW BEL7MON BRI-6 BRI-7. 1082

BRI-9 PAL-61 17, 30251, EmKa

HERLUF, FO, HK KI POPE HHKB. APD

JOO194, JOO196, J00203 J00201 X03069. M11161

M33600

X70251 M17378. M16957. M20430 M16958. M30180 L23964 M35159 L23963 MI 6959, M30179 M20504 LO2545 L14852 x74343 x75444 M17379. X04054

-

M91807, LO7767 M27689 M81743 X75441 K02776, M17381.

M15068 M20548-50, Ml9556

- XO2902, M15073, M1569-74 M15070, L13875

M3777l M37770

M37769, M64794 M81670, M36879 M81700, M55615 M77672 M94460 X65031 X68272 X70788 L14481 X71610 L21985 M11867 M34316 M17382 M21966, M22047-49 - M34317 M84188 M98436, D14352 X73027 L21984 L21983 x75347 L23986 L23987. L26306

L23989 X76194, L29081, UO9200

M27635, M27509 M27510 548645 M17383, XD4056 - wT46: CMCC

HAG. MRS, EGS, OSC, MGA, JRS. 11 81, 1183, 2708, IH, JS, M34320-23, M57599

X52451. X16649.

MK. SD 1124, 1125 M34320-24 TA, JP. HS, EP. DES.01 M57600 MW M61899

(731b (74)b

(75) (761b

A. Smith

A. Smith

L-A. Baxter-Lowe (103). L-A Baxter- i o w i L-A. Baxter-Lowe (80). k Smith. B. Schmeckpeper

8

Nomenclature for factors of the HLA system, 1994

Table 5 Continued

HLA-DR HLA-0-associated Individual or Cell Line HLA Serological (T-celldefined) Previous from which Accession Allelesa Specificities Specificities Equivalents the sequences was derived Number

References or Submitting author(s)

ORB1'1307 DRB1'1308 DRB1'1309 ORB1'1310 ORB1'1311 DRB1'1312

DRBl '1 313 DRB1'1401 DRB1'1402 DRBl'1403 DRB1.1404 DRB1'1405 DRB1'1406 DRB1'1407 DRB1'1408 DRB1'1409 DRB1'1410 DRB1'1411 DRB1'1412 ORB1'1413 ORB1.1414 ORB1'1415 ORB1'1416 ORB1'1417 DRB1'0701 DRBl '0801 DRB1'08021 DRB1'08022 DRB1'08031 DRB1'08032 ORB 1'0BO4 1' ORB1'08042 DRB1.0805 ORB 1'0806

DRBl'OB07 DRB1'0808 ORB 1'0809 DRB1'0810 DRBl'O811 DRB1'09011 DRB1'09012 DRB1'1001 DRB3'0101

DRB3'0201 DRB3'0202 DRB3'03fJl ORB4'01

DRB4'D1O1lc ORB4'01012N ORB4'0102 ORB4'0103 ORBS0101 DRBS'OI 02 DRBS'02D1 DRBS0202 DRB5'0203 DRB6*0101

DR86'0201

OR86'0202

DRB7'01011 ORB7'01012

- DR13(6)

D R I 3(6) DR13(6)

-

-

- DR14(6) OR1 4(6) OR1 403 OR1 404 DR14(6) OR1 4(6) OR1 4(6) DR14(6) DR14(6) - - - - - - - - OR7 OR8 DR8 OR8 OR8 DR8 DR8 OR8 OR8 OR8

OR8 DR8 DR8 OR8 OR8 OR9 OR9 D R I 0 OR52

OR52 DR52 OR52 OR53

OR53 OR53 DR53 DR53 DR51 OR51 DR5l DR51 OR51 -

-

-

- -

- Dw9 Dw16 -

- Dw17. Dw'DB1' Dw8.1 Dw8.2 Dw8.2 Dw8.3 Dw8.3 -

- Ow23 Dw23

Dw24

Ow25 Ow25 Ow26 Dw4, DwlO, Dw13. Dwl4, Owl 5, Dwl7, Ow23 Owl 7 D w l l

Dw4 Dw2 Owl 2 Dw21 Dw22

-

-

- -

DRBl'JJY DRBl'SHN JJY, SHN L06847, D13189 - THA LO3531 ORBl'YUN MJD L23534 13NEW ARA X75442 - H108, HER-2698 X74313, X75445 DR13BRA. DR13.7 650, 651, 681, BRI-8 L25427. L23988

DR81'13GDR GIDRA-091 D l 7742 DRw6b I 4 1 ~ 6 , TEM X04057

JX6 MI - ORBl'LY10, DRw6b.2 CEPH-137502, KGU M34372 DRB1'14c 36M, 38M M33693, M60209 DRB1'14.GB. 14.6 GB. SAS5041, SASS080 M63927, M74032 14.7 PNG141. PNG196 M74030

- AMALA (LIA.AZL)d -

A01.14.8 AB4 A83 DRwl4x l l ORB1 'YOS

DRB174N DRB1'14af

141 2T

-

-

- - DRw8-SPL DRw8b ORWE-TAB

RB1066-1 ,OR8-V86

DR8-A74

-

-

DR8.6

DRBBZ O8New DR8.7 LP10-1 DRBTL - - - DR3 111, DRw6a 111

ORw6b 111 pDR5b 3 - -

- ORB4 null DRB4'1CML

DR2A Dw2 DR2A Dw12 DRZA Ow21 DR2A Ow22 DRBYHK DRBo'0101. DRBXll

DRBX21, DRBVI

-

DRBo'0201, DABX22. ORB6111 DRBy1

HV178, PNG198. PNG202 M77673, M74031 1103 M77671 ABCC31 M77670 MARBrun. MARMari. MARMarg ME4238 YOS 016110 GRC138 L21755 AD-2927, AD-3798. IHL AD036 L17044 DM. U02561 ~ ~~~

FVA-0166 X76195 #1531 O-LN X76938 BURKHAROT, MA". LBF M I 6941, M17384, UO9201 MADURA M17386 SPL OLL TAB089 KT, FD, POPE M27511 1066, 11 27. PM CAY3, CAYS. CAY92. CAY96 L10402 MS ME4357 RBL 824, RBL 8124. SFI. BOU. M87543, ME6590 ACG AG. RG. 12. 1 4 L22341 ETH3754 x75443 BRI-10 L23990 K.R., R.R. L19054 ARAO16, ARAC25 L29082 ISK DKB M17387 RAJI, NASC M20138 AVL, HHKB. DM28, DM29, CMCC 4Iw6, WT49. DM24 M17380, V00522 SWEIG WT46. CMCC -

PRIESS, FS, DM24, DM29, KO2775 MMCC MANN M16942 DBB - C.M.L. LO8621 MJ4, BOLETH M15178-9, M20555, M19556 PGF, ROF-NL M17377, Mt6954. M20429 BGE. OH0 M16955, M30182 AZH, MN-2 M16956, M30181 REM (RML)d M20503 HK55 M91 OD1

M2070782. HON, SAS6211 PGF, 00208915, CGG. BA, E4181324 RML. KASO11 M83204, ME3894

M84446, M34315

X04055. X0458

LBF, DKB. BURKHAROT, KT3, M17385, M17388, M15071-2.

BAC, BRD-2. HOM-2, KASI 16, X53357, ME3892

M77284-7, X53358, ME3893

BOLETH. BH13 K02772-4, L31617 PITOUT L31618

(1 12) (1 13) (114) J. McCluskey, C. Witt 0. Olerup (80) (1 15) (116)b, (117)e

(104)b

(118)

(119, 120)

A. Smith (80) L-A. Baxter-Lowe (121) A. Smith

(122)b (84, 85)b

(84)b

(84. 85)b

(125), J. Bidwell J. Bidwell

a Allele names given in bold type have been assi ned since the 1991 Nomenclature report. This reference is to a confirmatory sequence. This sequence has been previously assigned with a four-digit allele name. Cell line IS also known by alternative name. This reference is to a corrected sequence. ' These sequences can only be assigned a two-digit allele name due to incomplete sequence information.

? "

Bodrner et al.

Table 6 Designations of HLA-DR alleles

HLA-DR HLA-Dassociated Individual or Cell Line References or HLA Serological (T-cell-defined) Previous from which the Accession Submitting Allelesa Specificities Specificities Equivalents sequence was derived Number author(s)

DQA1'0101 - DRAl'O102 -

DRAl'O103 -

DRA1'0104 -

DRA1'0201 -

DRA1'03011 -

DRA1'03012 -

DRA1'0302 -

DRA1'0401 - DQA1*0501e - DRA1'05011 - DRA1'05012 - OQAl"05013 - OQAl*O502 - ORA1'0601 - DRB1'0501 DR5(l)

DRB1'0502 DR5(1) DRB1'05031 DR5(1) DRB1'05032 DR5(1)

DRB1.0504 - 0Q61'06011 DR6(1) 0~61'06012 DR6(l) DRB1'0602 DR6(l) DQB1'0603 DQ6(l) DRB1'0604 DR6(l) 01J61'06051c DR6(l)

0o61'06052 DR6(l) DQB1'0606 - OQ61'0607 - UQBl*O608 - UQ61.06Og - DQB1'0201 DR2

0961'0202 DQ2 DQB1'0301 DR7(3)

DRB1.0302 D08(3)

DRB1'03031 D09(3) DRB1'03032 DR9(3) DRB1'0304 DR7(3)

DRB1'0401 DR4 DRB1'0402 DQ4

OQBl*O305 -

Dwl Dw2, w21, w19

Dwl8, wl2, w8, Dw'FS' Ow9

Dw7, w l l

Dw4, wl0, wl3, w14, w15 Dw23

Dw23

Dw8, Dw'RSH' Dw3, w5, w22 Dw3 Dw5 Dw22

Dw8 Dwl

Dw21 Dw9 Dw9

-

- Dw12, w8 Dw12, w8 Dw2 Dw18, Dw'FS' Dw19 Dwl9

Dwl9 - - - - Dw3

Dw7

DRA 1.1, 1.9 LG2, BML - DQA 1.2, 1.19,l.AZH PGF, LB, CMCC, AZH, WT46, -

DRA DRA 1.3, 1.18, APR TAB, FPF, WVB, 2012 M34320-3 DRwSDRwl - 11 83, 201 3, 201 2, 2708, M34314 (126)

31227AB0, EK, KOSE, DEK, REN

DM29 MMCC, JV, NIN, BML. DM24, M29613, M29616 DM29, BOLETH

DRA 2. 3.7 LG-10, BEl, DM24, DM28, - (84)'

DRA 3, 3.1, 3.2

DQA 3, 3.1, 3.2, DR9- DKB DRw3 DRA 3. 3.1, 3.2. DR9- ISK

(127, 84)'

-

M11124 . . , DOw3 DRA 4.2, 3.8 DRA 4.1, 2 DRA 4.1, 2 DRA 4.1, 2 DRA 4.1, 2

DQA 4.3

DRwl.1 DRB 1.2, 1.21 DRB 1.3, 1.9, 1.3.1 ORB 1.3. 1.9, 1.3.2

-

DRB 1.1, DRwl 0-

DOE 1.9 DRB 1.4. 1.1 2 DRB1'0601 var. DRB 1.5, 1.2 DRB 1.6, 1.1 8 DRB 1.7, 1.1 9 DOE 1.8, DRBSLE 1.1 9b. 201 3-24 DRBl'MDVR-1 DRBl'WA1 DRB1'06BR11 DRBl'D6BR12 DRBl'O6AA DRB 2

DRB 2 Dw4, w5. w8, w13 DRB 3.1

Dw4, w10, w13, w14 DRB 3.2

Dw23 DRB 3.3 Dw23, w l l DQB 3.3 - DRB1'03HP, '03new - DRB1'03KC Dwl5 DRB 4.1. Wa Dw8, Dw'RSH' DRB 4.2, Wa

ARC, 2041, MADURA, SPL M33906 SWEIG - RAJI. CMCC X00370, KO1 160 MG3 - REM (RML)d M20506 EMA U03675 LUY - LG2, 45.1, BML, MVL, JR, MDR, WG, DC AZH, FJO - WT52, HU129, HU128 M65047 AP106, APlO9. AP110, - AP115 DG, R.F. M65046, M94773 AKIBA, BGE. TAB M65048 Sk, Rb M86740

WVB, APD, FPF, 2012 C M C , DAUDI, DM23, LD, WG M65051 CI, KT, MR. 2013

X03068, M65044

PGF, Wr, 2041, ROF-NL M20432 M65050. M34320

M36472, M34320, M65052

BEN53 L26325 LINE66 M86226 08-2779-0 M87041 R.W M87042 H0301, TRACHT L19951, L27345 Wr49, CMCC, QBL, M Z LD, VW, MOR, JNP, DM24, DM28, DM29, BEI. VAVY BURKHARDT, BH M81141, U07848 SWEIG, DRB37, NIN, JHA, JR, M65040 JME, DC. JGL, LUY, BML, DM23, MG3 BDLETH, FS, BIN40. WT51, DM24, DM29. MMCC. JS, VW, JNP, JDP DKB - DEB, KOZ, 51 12.1 03 HP, RG, M.M. G.P., M.A. X69169, X76554 KT3 M13279 ARC, OLN, MZ, 2041, SPL, MADURA

K02405, M65043, M81140

M65D38, KO1499

M65039. M60028 M74842, M83770, X76553

M33907, M65042

P. Zimmerman

(128)b

(129)' (130, 131, 128) (1 32) (133, 76)' (84)' (84, 128)b (1 34, 135, 136)

(1 37)

(129) (1 29) (138, 139) (84, 140)'

(141, 1401, R Monos (84)'

(84, 128, 85)'

(142)'

(144, 143) (1 43)b

(841b

a Allele names given in bold type have been assigned since the 1991 Nomenclature report. has been previously assigned with a four-digit allele name. name, as it is either published only as a protein or partial nucleotide sequence.

This reference is to a confirmatory sequence. This sequence This sequence can only be assigned a four-digit allele Cell also known by alternative name.

10

Nomenclature for factors of the HLA system, 1994

Table 7 Designations of HLA-DP alleles

Associated Individual or Cell Line References or HLA HLA-DP Previous from which the Accession Submitting Allelesa Specificities Equivalents sequence was derived Number author(s)

DPA1'0101 - DPA1'0102 - DPAl'D103 - DPA1'0201 - DPA1'02021 - DPA1'02022 -

LB141LB24. DPAl

DPw4al DPA2, pDArl3B 2.21 2.22

PSBa-31 8 LB. PRIESS X00457, KO1506 LG2 BDLETH, 3.1.0 X031 DO (1 25)b DAUDI, AKlBA CB68 M83906, L11642 (1 45)b LKT3, KT17. WI-L2 NS. CT46, EsSm, M83907, L11641 (1 45)b GlWh AMAl T7526 LUY, RSH, P0077, FB11

M83908 M83909, L11643 (145)b M83129, M83664, M62338. X72070 (146, 147, 148),

M. Tilanusb L19220, L27662 (149), A. Begovich

DPA1'0301 - DPA1'0401 - DPB1'OIO1lc DPwl

3.1 4.1 DPBl ,DPwl b

DPB1'01012 DPwl DPB1'0201d DPw2 DPB1'02011 DPw2 DPB1'02012 DPw2 DPB1.0202 DPw2 DPB1'0301 DPw3 DPB1'0401 DPw4

DPBl 'WA6 DPB2.1 DPB2.1 DPB2.1 DPB2.2 DPB3 DPB4.1, DPw4a

LINE 101, AH1457 JY LB 45.1, WJR076 QBL, DUCAF

HHKB, BDLFTH, PRIESS, LCl1, KASO11

SLE, PRIESS, ETH9-0226

X01426 M62328. X03067 M62329, X72071 M. Tilanusb M62334, X02964, X03023, X78044 M. Tilanusb M62326, M23675, KO161 5, NO001 0. M. Tilanusb

X02228, X00532. X72072 M62327, M21886 M62333, X72073 M. Tilanusb M62335, X72074 M. Tilanusb M62331 M62341, X72075 M. Tilanusb M85223, M62342. X072076 M. Tilanusb M62336, X78046 M. Tilanusb

M62337, X72077 M. Tilanusb M31778, M62343, X72078 M. Tilanusb M31779, M62339, X72079 M. Tilanusb M31780, M62332, X72080 M. Tilanusb M31781, M62344, X72082 M. Tilanusb M62340 M62330, X72081 M58608, M63508 (151, 152, 153).

M23906-9, X03022, XO30025-8,

L23399 (1 50)

J. Bidwell M97685 (1 54) M77659, M83915, M84621, M80300 (1 55)b M77674. M83919

DPB1'0402 DPw4 DPB1'0501 DPw5 DPB1'0601 DPw6 DPB1'0801 - DPB1'0901 - DPB1'1001 - DPB1'l lO1lc - DPB1'1101Z - DPB1'1301 - DPB1'1401 - DPB1'1501 - DPB1'1601 -

DPB1'1701 - DPB1'1801 - DPBl^l901 - DPB1'2001 l C -

DPB4.2, DPw4b DPB5 DPB6 DPB8 OPB9, DP'Cp63' DPBlO DPB11

OPE1 3 DPBl4 DPBl5 DP516 DPBl7 DPB18 bPBl9

-

00s. DPB-JA

APD, BURKHARDT HAS, LKT3 JMOS, FB11 PlAZ TOKUNAGA BM21, SAVC CRK, AVE G AH696 NB, KASl l6 8268, KASOl 1 PLH JRA, WT46 JRAB, LBUF JCA CB6B 00s. ARENT, BEL8-CC

NT GM, PE152, PE174. C1, T7527 HV152, HV385. SAS60103, SAS60106 DO20891 5, UK3082, UK5496, PT35. IT22, 1132 UK7430 PE146 LINE70

LINE92, H033 157. I1 47, JOG1 489 RBLB66, NG105, NG113, PNGll2, PNG177, SCZ244

168. 1147, 16. PE103, JOG1427, JOG1 471 NG78. PNG167 H023 H026, DH67 AH1450, AH521 SASBE41, THMl, KT LINE41 THKK

4-BEN ND2

AH1377, EB5, ETH-0245

DPB1'20012 - DPB1'2101 - DPB1'2201 -

DPBl'BRI6 DPB-GM, DPB30, NewD DPBl 'AB1, NewH

DPB1'2301 - DPB32, NewB M83913, M84014 (1 45, 1 50)b

DPBl'2401 - DPB1'2501 - DPB1'2601 lC - DPB1'26012 - DPB1'2701 - DPB1.2801 - DPB1'2901 -

DPB33, NewC DPB34, NewE DPB31, WA2 DPBl'WA8 DPB23, WA3 DPB21. JAVA2 DPB27, NewG

M83914 M83916 M86229 L24387 M84619, M86230 M84617, LO0599 M84625, M83918, LO1 467

(1 56)

(1 57)b (1 58)b

M. Tilanusb (1 57)b

DPB1'3001 - DPB1'3101 -

DPB28 DPB22, NewF, JAVA1

M84620, X78045 M84618, M83917, LO0598

DPB1'3201 - DPB1'3301 - DPB1'3401 - DPB1'3501 - DPB1'3601 - OPB1'3701 - OPB1'3801 -

DPB24, New1 DPB25 DPB26 DPB29 New A, SSKP OPBl'WA4 SSKl

M84622, MB5222 M84623 M84624 M84626 M83912, D10479. D10882 M87046 D10478

Cont. on next page

11

Bodmer et al.

Table 7 Continued

~~ ~ ~~ ~ ~ ~~ ~~

Associated Individual or Cell Line HLA HLA-DP Previous from which the Accession Allelesa Specificities Equivalents sequence was derived Number

~~~~~

References or Submitting author(s)

DPB1.3901 DPB1'4001

OPB 1'41 01 DPBl'4401 DPB 1'450 1 DPB1'4601 DPB1'4701 DPB1'4801 DPB1'4901 DPB1.5001 DPB1'5101

DPB1'5201 ' DPB1'5301

DPB1'5401 DPB1'5501

DPB1 'BR14 DPBl'BRI5, WA5

DPB2.3 STCZ DPBl 'NM DPBI'NIB DPBl'O2KI: 'SUT -

- DPBl'WA7, *EAl, 'JYO

- DPBl New2 DPBl New3

EM, ETH-0203 50, LINE103, LINE105, LINE116, LINE1 17, LINE1 19 EB39, H062 HT scz259, scz244 c212 UE.C. SAJOOB, SAJll9, SUT SE107 H021 OIEDE

8, JYO HD82 EB26

C2#3,1 SEEN, NMDP#00800-2553-

ETH-0222 ETH-0271

M97686, X78043 M97684, L19219. L23400

D13174 LO1 466 LO9236 LO7768 01 4344, 010834 L17314 L17313 L17311 L17310, L19219, L27073, D28809

L22076 L22077 X78042 X78041

(154) M. Tilanus (154, 149, 150)

a Allele names given in bold type have been assigned since the 1991 Nomenclature report. This reference is to a confirmatory sequence. This sequence has been previously assigned with a four-digit allele name. This sequence can only be assigned a four-digit allele name, as it is either published anly as a protein or partial nucleotide sequence.

Table 8 Designations of HLA-DM alleles

HIA Previous Individual or Cell Line from which Accession References Allelesa Equivalents the sequence was derived Number

OMA'Ol 01 DMA'OlO2 DMA'0103 DMA*0104

DMB'O101 DMB'OlO2 OMB'O103 OMB'O104

RING6 DMA-lle 140 DMA3.2 OMA3.4

RING7

DMB-Thr 179 DMB3.4

DMB-GIu 143

JU, MANN AZL

BM21

JY, MANN YAR EM16

HDM-2

CEPH 23-01

X62744 224753 U04878 U04877

2231 39 224750 224751 U00700

a Allele names given in bold type have been assigned since the 1991 Nomenclature report.

Table 9 Designations of TAP alleles

TAP Previous Individual or Cell Line from which Accession Allelesa Equivalents the sequence was derived Number References

~ ~ ~~ ~~ ~~ ~

TAP1'0101 RING4, PSF(Y3), TAPlA U937, LCL721.45. HB00028, HE00032 X57522, X57521, L21204 TAP1'02011 TAPl B CK L21206 TAP1'02012 TAP1 E H EH L21205 TAP1'0301 TAPlC JT L21208 TAP1'0401 TAPl D HE00031 L21207

TAP2'0101 RINGllA, TAP2A CEM-CCRF M84748 (1 77) TAP2'0102 TAP2E JY 222936 (178) TAP2'0201 RING1 1 B, TAP2B 0x3 222935 (177)

a Allele names given in bold type have been assigned since the 1991 Nomenclature report.

12

Nomenclature for factors of the HLA system, 1994

Footnote:

New sequences should be communicated to S . Marsh to receive official names.

Address: S. G. E. Marsh Tissue Antigen Laboratory, Imperial Cancer Research Fund, 44 Lincoln’s Inn Fields, London WC2A 3PX United Kingdom Telephone: 44 (UK)-71 (London)-269-3534 FAX: 44 (UK)-71 (London)-83 1-6786

References

I . WHO-Nomenclature-Committee. Bull. WHO 1968: 39: 483.

2. WHO-Nomenclature-Committee. WHO terminology re- port. In: P. I. Terasaki ed. Histocompatibility Testing, 1970, Copenhagen: Munksgaard, 1970: 49.

3. WHO-Nomenclature-Committee. Bull. WHO 1972: 47: 659.

4. WHO-Nomenclature-Committee. Bull. WHO 1975: 52: 261.

5 . WHO-Nomenclature-Committee. Bull. WHO 1978: 54: 461.

6. WHO-Nomenclature-Committee. In: P. I. Terasaki ed. Histocompatibility Testing, 1980, Los Angeles: UCLA Tissue Typing Laboratory, 1980: 18-20.

7. WHO-Nomenclature-Committee. Nomenclature for fac- tors of the HLA system 1984. In: E. D. Albert, M. P. Baur and W. R. Mayr ed. Histocompatibility Testing, 1984, Berlin: Springer-Verlag, 1985: 4-8.

8. Bodmer WF, Albert E, Bodmer JG, Dupont B, Mach B, Mayr WR, Sasazuki T, Schreuder GMT, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA system, 1987. In: B. Dupont ed. Immunobiology of HLA, New York: Springer-Verlag, 1989: 72-79.

9. Bodmer JG, Marsh SGE, Parham P, Erlich HA, Albert E, Bodmer WF, Dupont B, Mach B, Mayr WR, Sasasuki T, Schreuder GMT, Strominger JL, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA system, 1989. Tissue Antigens 1990: 35: 1-8.

10. Bodmer JG, Marsh SGE, Albert E, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasasuki T, Schreuder GMT, Strominger JL, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA system, 1990. Tissue Antigens 1991: 37: 97-104.

1 1. Bodmer JG, Marsh SGE, Albert E, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasasuki T, Schreuder GMT, Strominger JL, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA system, 1991. In: T. Tsuji, M. Aizawa and T. Sasazuki ed. HLA 1991, Oxford: Oxford University Press, 1992: 17-3 1.

12. Geraghty DE, Koller BH, Pei J, Hansen JA. Examination of four HLA Class I pseudogenes. Common events in the evolution of HLA genes and pseudogenes. J . Immunology

13. Krangel MS. Unusual RNA splicing generates a secreted form of HLA-A2 in a mutagenized B lymphoblastoid cell line. Embo J 1985: 4: 1205-1210.

14. Belich MP, Madrigal JA, Hildebrand WH, Zemmour J, Williams RC, Luz R. Petzl-Erler ML. Parham P. Unusual

1992: 149: 1947-1956.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

31.

33.

HLA-B alleles in two tribes of Brazilian Indians. Nature

Barber DF, Fernandez JM, Guttridge MG, LApez de Cas- tro JA. Primary structure of a new HLA-A2 subtype: HLA-A*0213. Immunogenelics 1994: 39: 378. Lin L, Tokunaga K, Ishikawa Y, et al. Sequence analysis of serological HLA-A1 1 split antigens, Al I . 1 and A 1 1.2. Tissue Antigens 1994: 43: 78-82. Madrigal JA, Hildebrand WH, Belich MP, Benjamin RJ, Little AM, Zemmour J, Ennis PD, Ward FE, Petzl-Erler ML, du Toit ED, Parham P. Structural diversity in the HLA-AIO family of alleles: correlations with serology. Tissue Antigens 1993: 41: 72-80. Ishikawa Y, Tokunaga K, Lin L, Imanishi T, Saitou S , Kimura A, Kashiwase K, Akaza T, Tadokoro K, Juji T. Sequences of four splits of HLA-A10 group: Implications for serological cross-reactivities and their evolution. Human Immunology 1994: 39: 220-224. Olerup 0, Daniels T, Baxter-Lowe LA. Correction of the A*3001 sequence. Tissue Antigens 1994: in press. Choo SY, Starling GC, Anasetti C, Hansen JA. Selection of an unrelated donor for marrow transplantation facili- tated by the molecular characterisation of a novel HLA- A allele. Human Immunology 1993: 36: 20-26. Kato N, Kikuchi A, Kano K, Egawa K, Takiguchi M. Molecular analysis of a novel HLA-A33 subtype associ- ated with HLA-B44. Tissue Antigens 1993: 41: 211-213. Schnable E, Stockinger H, Madjic 0, Gaugitsch H, Lind- ley IJD, Maurer D, Hajek-Rosenmayr A, Knapp W. Acti- vated human T lymphocytes express MHC Class I heavy chains not associated with P2-microglobulin. J. Experi- mental Medicine 1990: 171: 1431-1442. Domena JD, Hildebrand WH, Bias WB, Parham P. A sixth family of HLA-A alleles defined by A*8001. Tissue Antigens 1993: 42: 156-159. Wagner AG, Hughes AL, Iandoli ML, Stewart D, Herbert S, Watkins DI, Hurley CK, Rosen-Bronson S. HLA- A*8001 is a member of a newly discovered ancient Family of HLA-A alleles. Tissue Antigens 1993: 42: 522-529. Starling GC, Witkowski JA, Speerbrecher LS, McKinney SK, Hansen JA. Choo SY. A novel HLA-A*8001 allele identified in African American population. Human Immu- nology 1994: 39: 163-168. Domena JD, Azumi K, Bias WB, Parham P. B*1401 enco- des the B64 antigen: the B64 and B65 splits of B14 differ only at residue I I , a buried amino acid. Tissue Antigens 1993: 41: 110-111. Domena JD, Little A-M, Arnett KL, Adams EJ, Marsh SGE, Parham P. A small test of a sequence-based typing method: Definition of the B* 1520 allele. Tissue Antigens in press. Choo SY, Fan LA, Hansen JA. Allelic variations clustered in the antigen binding sites of HLA-Bw62 molecules. Im- rnzcnogenetics 1993: 37: 108-1 13. Hildebrand WH, Domena JD, Shen SY, Lau M, Terasaki P, Bunce M, Marsh SGE, Guttridge MG, Bias WB, Parham P. HLA-BI 5: A widespread and diverse family of HLA-B alleles. Tissue Antigens 1994: 43: 209-218. Domena JD, Little AM, Madrigal AJ, Hildebrand WH, Johnston-Dow L, du Toit E, Bias WB, Parham P. Struc- tural Heterogeneity in HLA-B70, a high frequency antigen of Black populations. Tissue Antigens 1993: 42: 509-5 17. Rodriguez SG, Johnson AH, Hurley CK. Molecular characterisation of HLA-B71 from an African American Individual. Humon Immitnology 1993: 37: 192-194. Choo SY, Fan LA, Hansen JA. A novel HLA-B27 allele maps 827 allospecificity to the region around position 70 in the a I domain. J . Immunology 199 I : 147: 174-1 80. Seemann GH. Rein RS. Brown CS, Ploegh HL. Gene

1992: 357: 326-329.

13

Bodmer et at.

conversion-like mechanisms may generate polymorphism in human class I genes. Einbo J 1986: 5: 547-52.

34. Weiss EH, Kuon W, Dorner C, Lang M, Riethmiiller G. Organization, sequence and expression of the HLA-B27 gene: A molecular approach to analyze HLA and disease associations. Immunobiology 1985: 170: 367-380.

35. Coppin HL, McDevitt HO. Absence of polymorphism between HLA-B27 genomic exon sequences isolated from normal donors and ankylosing spondylitis patients. J. Im- munology 1986: 137: 2168-2172.

36. Szots H, Riethmiiller G, Weiss E, Meo T. Complete se- quence of HLA-B27 cDNA identified through the char- acterization of structural markers unique to the HLA-A, - B, and -C allelic series. Proc. Natl. Acad. Sci. USA 1986: 83: 1428-1432.

37. Watkins DI, McAdam SN, Liu X, Strang CR, Milford EL, Levine CG, Garber TL, Dogon AL, Lord CI, Ghim SH, Troup GM, Hughes AL, Letvin NL. New recombin- ant HLA-B alleles in a tribe of South American Amerindi- ans indicate rapid evolution of MHC class I loci. Nature 1992: 357: 329-333.

38. Vilches C, de Pablo R, Kreisler M. Nucleotide sequence of B*2706. Immunogenetics 1994: 39: 219.

39. Hildebrand WH, Domena JD, Shen SY, Marsh SGE, Bun- ce M, Darke C, Parham P. The HLA-B7Qui antigen is encoded by a new subtype of HLA-B27. Tissue Antigens 1994: in press.

40. Theiler G, Pando M, Delfino JM, Takiguchi M, Satz ML. Isolation and characterisation of two new functional subtypes of HLA-B35. Tissue Anfigens 1993: 41: 143-147.

41. Steinle A, Reinhardt C, N o h e r E, Uchanska-Ziegler B, Ziegler A, Schendel D. Natural microheterogeneity in HLA-B35 alleles influences peptide-dependent allorecog- nition by cytotoxic T cells but not binding of a peptide- restricted monoclonal antibody. Human Immimology 1994

42. Little AM, Domena JD, Hildebrand WH, Shen SY, Barber LD, Marsh SGE, Bias WB, Parham P. HLA-B67: A mem- ber of the HLA-B16 family that expresses the ME1 epi- tope. Tissue Antigens 1994: 43: 3843.

43. Muller CA, Engler BG, Gekeler V, Steiert I, Weiss E, Schmidt H. Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6. Im- minogenetics 1989: 30: 200-7.

44. Kato N, Karaki S, Kashiwase K, Miiller C, Akaza T, Juji T, Kano K, Takiguchi M. Molecular Analysis of HLA- B39 subtypes. hnmunogenetics 1993: 37: 212-216.

45. Ways JP, Lawlor DA, Wan AM, Parham P. A transposable epitope of HLA-B7, B40 molecules. Immrinogenetics 1987:

46. Kawaguchi G, Kato N, Kashiwase K, Karaki S, Kohsaka T, Akaza T, Kano K, Takiguchi M. Structural analysis of HLA-B40 epitopes. Human Immunology 1993: 36:

47. Domena JD, Johnston-Dow L, Parham P. The B*4002 allele encodes the B61 antigen: B40* is identical to B61. Tissue Antigens 1992: 40: 254-256.

48. Keever CA, Leong N, Cunningham I, Copelan EA, Avalos BR, Klein J, Kapoor N, Adams PW, Orosz CG, Tutschka PJ, Baxter-Lowe LA. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bane Marrow 7iunsplnntotian 1994: 13: in press.

49. Yao Z , Keller E. Scholz S, McNicolas A, Volgger A. Albert ED. Identification of two major HLA-B44 subtypes and a novel B44 sequence: Oligotyping and solid phase sequencing of PCR products. Humin Ininii/nu/ogv 1994: in press.

50. Gauchat-Feiss D. Breur-Vriesendorp BS. Rul'er N. Jeannet

38: 261-269.

25: 323-8.

193-198.

M, Rossnek E, Tiercy J-M. Sequencing of a novel func- tional HLA-B44 subtype differing in two residues in the alpha 2 domain, (B*4404). Tissue Antigens 1994: in press.

51. Pohla H, Kuon W, Tabaczewski P, Doerner C, Weiss EH. Allelic variation in HLA-B and HLA-C sequences and the evolution of the HLA-B alleles. Immunogenetics 1989: 29:

52. Cereb N, Choi JW, Riu KZ, Yang SY. HLA-B*5105, a newly identified B51 IEF variant. Tissue Antigens 1994: in press.

53. Hayashi H, Ennis PD, Ariga H, Salter RD, Parham P, Kano K, Takiguchi M. HLA-B51 and HLA-Bw52 differ by only two amino acids which are in the helical region of the ctl domain. J. Immunology 1989: 1 4 2 306-11.

54. Parham P, Arnett HK, Adams EJ, Barber LD, Domena J, Hildebrand WH, Little A-M. The HLA-B73 antigen has a most unusual structure that defines a second lineage of HLA-B alleles. Tissue Antigens 1994: in press.

55. Hildebrand WH, Dornena JD, Parham P. Primary struc- ture shows HLA-B59 to be a hybrid of HLA-B55 and HLA-B51, and not a subtype of HLA-BS. Tissue Antigens 1993: 41: 190-195.

56. Vilches C, de Pablo R, Herrero MJ, Moreno ME, Kreisler M. HLA-B73, an atypical HLA-B molecule carrying a Bw6-epitope motif variant and a B pocket identical to HLA-B27. Imrnunogenetics 1994: in press.

57. Grassi F, Meneveri R, Gullberg M, Lopalco L, Rossi GB, Lanza P, De Santis C, Brattsand G, ButtB S , Ginelli E, Beretta A, Siccardi AG. Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by Class I major histocompatibility complex heavy chains. J. Experimental Medicine 1991: 174: 53-62.

58. Ellis SA, Strachan T, Palmer MS, McMichael AJ. Com- plete nucleotide sequence of a unique HLA Class I C locus product expressed on the human choriocarcinoma cell line BeWo. J. Immunology 1989: 142: 3281-3285.

59. Petersdorf EW, Stanley JF, Martin PJ, Hansen JA. Mol- ecular diversity of the HLA-C locus in unrelated marrow transplantation. Tissue Antigens 1994: in press.

60. Steinle A, NoBner E, Schendel D. Isolation and character- isation of a genomic HLA-Cw6 clone. Tissue Anfigens 1992: 39: 134-137.

61. Vilches C, de Pablo R, Herrero MJ, Moreno ME, Kreisler M. Molecular cloning and Polymerase Chain Reaction- Sequence-Specific Oligonucleotide detection of the allele encoding the novel allospecifcity HLA-Cw6.2 (Cw* 1502) in Spanish Gypsies. Human Immunology 1993: 37:

62. Davidson WF, Kress M, Khoury G, Jay G. Comparison of HLA Class I gene sequences: Derivation of locus-specific oligonucleotides probes specific for HLA-A, HLA-B, and HLA-C genes. J. Biol. Chemistry 1985: 260: 13414-13423.

63. Takiguchi M, Nishimura I, Hayashi H, Katakl S, Kariyo- ne A, Kano K. The structure and expression of genes encoding serologically undetected HLA-C locus antigens. J. Immunology 1989: 143: 1372-8.

64. Cereb N, Choi JW, Lee S, Maye P, Kong Y, Yang SY. Identification of two new HLA-C alleles, Cw*1203 and Cw* 1402, from the sequence analysis of seven HLA homo- zygous cell lines carrying HLA-C blank. Tissue Antigens 1994: in press.

65. Cianetti L, Testa U, Scotto L, La VR, Simeone A, Boccoli G. Giannella G, Peschle C, Boncinelli E. Three new class I HLA alleles: structure of mRNAs and alternative mech- anisms of processing. I/irmunogenetics 1989: 29: 80-9 1.

66. de Pable MR, Vilches C . Moreno ME, Kreisler M. A novel HLA-C allele (Cw* 1504) related to the Cw6.2 phenotype. Iwirrinagmrtics 1993: 39: 79.

67. Vilches C, Herrero MJ. de Pablo ME. Bunce M, Kreisler

291-307.

259-263.

14

Nomenclature for factors of the HLA system, 1994

85. Horn GT, Bugawan TL, Long CM, Manos MM, Erlich HA. Sequence analysis of HLA class I1 genes from insulin- dependent diabetic individuals. Human Immunology 1988:

86. Eberle M, Baxter-Lowe LA. A silent mutation in HLA- DRBl*O301 can affect oligotyping. Tissue Antigens 1992:

87. Buyse I, Edmonds M P, Bouillon R, Bex M, De Canck I, Marynen P, Cassiman JJ. Novel Class I1 HLA DRBI, DRB4 and DPBl alleles found in the Belgian population. Imrnunogenetics 1993: 38: 380.

88. Spies T, Sorrentino R, Boss JM, Okada K, Strominger JL. Structural organization of the DR subregion of the human major histocompatibility complex. Proc. Natl. Acad. Sci. U S A 1985: 82: 5165-9.

89. Anderson G, Larhammar D, Widmark E, Servenius B, Peterson PA, Rask L. Class I1 genes of the Human Major Histocompatibility Complex. J. Biol. Chemistry 1987: 262:

90. Curtsinger JM, Hilden JM, Cairns JS, Bach FH. Evol- utionary and genetic implications of sequence variation in two nonallelic HLA-DRB-chain cDNA sequences. Proc. Natl. Acad. Sci. USA 1987: 84: 209-213.

91. Gregersen PK, Goyert SM, Song QL, Silver J. Micro- heterogeneity of HLA-DR4 haplotypes: DNA sequence analysis of LD“KT2” and LD“TAS” haplotypes. Human Immunology 1987: 19: 287-92.

92. Morales P, Martinez-Laso J, Martin-Villa JM, Corell A, Vicario JL, Varela P, Pirez-Aciego P, Arnaiz-Villena A. High frequency of the HLA-DRB I *0405-(Dwl5)-DQw8 haplotype in Spaniards and its relationship to diabetes susceptibility. Human Immunology 199 I : 32: 170-175.

93. Petersdorf EW. Smith AG, Martin PJ, Hansen JA. HLA- DRBl first domain sequence for a novel DR4 allele de- signated DRBl*0413. Tissue Antigens 1997: 40: 267- 268.

94. Pile KD, Willcox N, Bell JI, Wordsworth BP. A novel HLA-DR4 allele (DRB1*0414) in a patient with Myas- thenia Gravis. Tissue Antigens 1992: 40: 264-266.

95. Tiercy JM, Gebuhrer L, Betuel H, Mach B, Jeannet M. A new HLA-DR4 allele with a DRI I alpha-helix sequence. Tissue Antigens 1993: 41: 97-101.

96. Middleton D, Hughes DJ, Trainor F, Graham CA, Savage DA. A n HLA-DRBI*04 first domain sequence (DRB1*0416) which differs from HLA-DRB1*0401 at co- don 59. Tissue Anfigens 1994: 43: 44-46.

97. Zhang S, Fernandez-Vina M, Falco M. CernE M, Rai- mondi E, Stastny P. A novel HLA-DRBI allele (DRB1*0417) in South American Indians. I~nmrmogenefics 1993: 38: 463.

98. Smith AG, Petersdorf E, Mickelson E, Guthrie LA, Regen L, Martin PJ, Hansen JA. HLA-DRBI First domain se- quences of two new D R l l alleles and one novel DR4 allele. Tissue Anfigens 1993: 42: 533-535.

99. Lin YN, Ren EC, Chan SH. A new DR11 allele in Sinapo- rean Chinese. Tissue Anfigens 1993: 41: 204205.

100. Bannai M, Tokunaga K, Lin L, Park MH, Kuwata S, Fujisawa K, Juji T. A new HLA-DRI IDRBI allele found in a Korean. Human Immunology 1994: 39: 230-232.

101. Middleton D, Hughes DJ, Williams F, Graham CA, Mar- tin J, Savage DA. A new DRBl allele DRBI*1107 - a combination of DRB I * I 1 and DRB 1 *03. Tissue Anfigens 1993: 42: 160-163.

103. Williams F, Hughes DJ. Middleton D. A new HLA- DRBI*I I allele (DRBI*I 109) differing at codons 32. 34 and 37. Tissue Antisgens iri press.

103. Smith AG. Safirman C. Kelso C, Ainar A. Hansen JA, Brnutbar C. Two new DR52 associated DRBl ullelrs, DRB I * 1 1 I 1 and * I3 12. idenlilird by PCRISSOP and

21: 249-63.

40: 150-152.

8748-8758.

M. Molecular characterization of a novel, serologically detectable, HLA-C allele: Cw* 1602. Human Immunology 1994: 40: in press.

68. Geraghty DE, Koller BH, Orr HT. A human major histo- compatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc. Natl. Acad. Sci. USA 1987: 84: 9145-9.

69. Shukla H, Swaroop A, Srivastava R, Weissman SM. The mRNA of a human class I gene HLA G/HLA 6.0 exhibits a restricted pattern of expression. Nucleic Acid Research 1990: 18: 2189.

70. Morales P, Corell A, Martinez-Laso J, Martin-Villa JM, Varela P, Paz-Artal E, Allende LM, Amaiz-Villena A. Three new HLA-G alleles and their linkage disequilibria with HLA-A. Immrinogenetics 1993: 38: 323-33 I .

71. Ellis SA, Palmer MS, McMichael AJ. Human Trophoblast and the choriocarcinoma cell line BeWo express a trunc- ated HLA Class I molecule. J. Immunology 1990: 144:

72. Pook MA, Woodcock V, Tassabehji M, Campbell RD, Summers CW, Taylor M, Strachan T. Characterization of an expressible nonclassical Class I HLA gene. Human Immunology 1992: 32: 102-109.

73. Hurley CK, Ziff BL, Silver J, Gregersen PK, Hartzman R, Johnson AH. Polymorphism of the HLA-DRI haplo- type in American Blacks. Identification of a DRI P-chain determinant recognized in the mixed lymphocyte reaction. J. Immunology 1988: 140: 4019-4023.

74. Coppin HL, Avoustin P, Fabron J, Huchenq A. Gamier JM, Thomsen M, De Preval C. Evolution of the HLA- DRI gene family. Structural and functional analysis of the new allele “DR-BON”. J. Immunology 1988: 144: 984-9.

75. Guignier F, Mercier B, Roz P, Ferec C, Saleun JP, Chatel- ain P. A novel DRBI*OI allele (DRB1*0104). Tissue Anti- gens 1993: 42: 42-44.

76. Lock CB, So AKL, Welsh KI, Parkes JD, Trowsdale J . MHC class I1 sequences of an HLA-DR2 narcoleptic. Imrntrnogenetics 1988: 27: 449-455.

77. Rosenlicht JW, Hartung K, Deicher H, Frey J . A novel HLA-DRB I-DR2 allele associated with HLA mistyping. Iinmunogenefics 1993: 37: 479.

78. Laforet M, Urlacher A, Tongio MM. A new HLA DR16 allele (DRB1*1604) with a short DR8 sequence. Tissue Antigens 1994: 43: 256-258.

79. Bettinotti MP, McNicholas A, Keller E, Andreas A. Scholz S, Albert E. DRB1*1605: a new DR2-DRBI allele found in a German family. Immunogenerics 1994: 39: 300.

80. Anholts JDH, Verduyn W, Parleviet J , Doxidis IIN. D’Amaro J, Giphart M, Persijn G, Schreuder GMT. Ir- regular PCR-SSO hybridisation patterns reveal seven new HLA-DRBI alleles related to DR2, DR3, DR6, DR8 and DRI I : implications for sequence specific priming. Human Immunology 1994: in press.

81. Gustafsson K, Wiman K, Emmoth E, Larhammar D, Bohme J, Hyldig NJ, Ronne H, Peterson PA. Rask L. Mutations and selection in the generation of class I1 histo- compatibility antigen polymorphism. Embo J 1984: 3:

82. Gorski J, Mach B. Polymorphism of human la antigens: gene conversion between two DR beta loci results in a new HLA-D/DR specificity. Narrrre 1986: 322: 67-70.

53. Bell JI, Denney DJ, Foster L. Belt T, Todd JA. McDevitt HO. Allelic variation in the DR subregion of the human major histocompatibility complex. Proc. Nirfl. .Aciitl Sci, USA 1987: 84: 6234-8.

84. Todd JA. Bell JI. McDevitt HO. HLA-DQB gene conti-ib- Utes to susceptibility and resistance to insulin-drprndent diabetes rnellitus. Nirfrtre 1987, 329: 599-604.

731-735.

1655-6 I .

15

Bodmer et a].

confirmed by DNA sequence. Tissue Antigens 1994: in press.

104. O'Brien R, Cram DS, Russ GR, Starr R, Tait B. Nucleo- tide sequences of the HLA-DRwl2 and DRw8 BI chains from an Australian Aborigine. Human Immunology 1992:

105. Noreen HJ, Santamaria P, Davidson ML, Rich S S , Segall M. Serology, restriction fragment length polymorphism, and sequence analysis of a unique HLA class I1 antigen, DR5x6. Human Immunology 199 1 : 30: 168-1 73.

106. Lee KW. DR6 in Koreans: D R l l frequently acts as a recipient gene to create DR13 alleles. Human Immunology

107. Kaneshige T, Hashimoto M, Murayama A, Kinoshita T, Hirasawa T, Uchida K, Inoko H. Serological and Nucleo- tide sequencing analyses of a novel DR52-associated DRBl allele with the DR 'HR5' specificity. Human Immu- nology 1994: 40: in press.

108. Home C, Goodfellow PJ, McDonald HL, Junker AK, Keown PA, Hoar DI. A new HLA-DRB1 allele formed by an intra-exonic interallelic crossover. Tissue Antigens

109. Yunis JJ, Kineke E, Yunis EJ. Characterisation of a new DRBl allele (DRBl*l3YUN) by PCR-SSOP and seq- uencing. Tissue Antigens 1994: 43: 54-57.

110. Dufosse F, Craco P, Becuwe D, Lemaitre V, Huart JJ. A novel HLA DR52-associated DRBl allele and its haplo- typic association. Tissue Antigens 1994 43: 270-272.

1 1 1. Yoshida M, Tokunaga KMS, Lin L, Nakazawa M, Ohtsu- ka R, Juji T. A new DR allele (DRB 1 * 13 13) from Papua New Guinea, generated by an intra-exonic recombination. Human Immunology 1994: in press.

112. Laforet M, Urlacher A, Falkenrodt A, Liore B, Parissiadis A,Tongio MM.Anew DR14allele(DRB1*14ll)contain- ing a short DR 1 1 sequence and its haplotypic association. Human Immunology 1993: 36: 179-185.

113. Hashimoto M, Kaneshige T, Kinoshita T, Murayama A, Asai S , Yamaski M, Nojima M, Ichikawa Y, Fukunishi T. A new DRI4-related DRBl allele, DRB1*1412 which differs from DRB1*1403 only at codon 86. Tissue Anfigens

114. Pando M, Theiler G, Melano R, Petzl-Erler ML, Satz ML. A new HLA-DR6 allele (DRB1*1413) found in a tribe of Brazilian Indians. Immunogenetics 1994: 39: 377.

115. Hashemi S , Aye MT, Zeibdawi A, Cole R, Goldstein R. A novel HLA-DRB1*14 allele (DRB1'1417). Tissue Antigens 1994: in press.

116. Young JA, Wilkinson D, Bodmer WF, Trowsdale J. Se- quence and evolution of HLA-DR7- and -DRw53-associ- ated beta-chain genes. Proc. Natl. Acad. Sci. USA 1987:

117. Guethfein LA, Bias WB, Schmeckpeper BJ. Re-evaluation of DRBl*0702: Evidence for only one allele, DRB 1 *0701, encoding the p chain of the HLA-DR7 antigen. Tissue Antigens 1994: 43: 124-128.

118. Titus-Trachtenberg EA, Rickards 0, De Steano GF, Erlich HA. Analysis of HLA class I1 haplotypes in the Cayapa indians of Ecuador: A novel DRBl allele reveals evidence for convergent evolution and balancing selection. Amer- ican Journal of Human Genetics 1994: in press.

119. Apple R, Erlich HA. Two new HLA DRBl alleles found in African Americans: Implications for balancing selec- tion at positions 57 and 86. Tissue Anfigens 1992: 40:

120. Benmamar D, Martinez-Laso J, Varela P, Bekhouchas F, Morales P, Arnaiz-Villena A. Evolutionary pathway of HLA-DR8 haplotypes and description of a new allele (DRB 1 *0806) in the Algerian population. Hirr~7tuz Inunu-

34: 147-151.

1993: 37: 229-236.

1993: 42: 141-143.

1994: 43: 133-135.

84: 4929-33.

69-74.

/lology 1993: 36: 172-178.

121. She JX, Zhang LP, Wakeland EK. Nucleotide sequence of a novel HLA-DRBI allele, DRBl*0806. Immunogenetics 1993: 39: 78 [Published erratum Immunogenetics (1994) 39: 379).

122. Merryman P, Gregersen PK, Lee S , Silver J, Nunez RA, Crapper R, Winchester R. Nucleotide sequence of a DRwlO beta chain cDNA clone. Identity of the third D region with that of the DRw53 allele of the beta 2 locus and as the probable site encoding a polymorphic MHC class I1 epitope. J. Immunology 1988: 140: 2447-52.

123. Sutton VR, Kienzle BK, Knowles RW. An altered splice site is found in the DRB4 gene that is not expressed in HLA-DR7, Dwl 1 individuals. Immunogenetics 1989: 29:

124. Grooms A, Dunckley H, Gao X, Serjeantson SW. DRBS'HK: A new HLA-DRB5 allele in Cantonese. Tissue Antigens 1992: 40: 210-21 I .

125. Lawrance SK, Das HK, Pan J, Weissman SM. The genom- ic organisation and nucleotide sequence of the HLA- SB(DP) alpha gene. Nucleic Acid Research 1985: 13:

126. Fogdell A, Olerup 0. The DQA1*0104 allele is carried by DRB1*1001- and DRB1*1401-positive haplotypes in Caucasians, black Africans and Orientals. Tissue Antigens 1994: in press.

127. Jonsson AK, Hyldig NJ, Servenius B, Larhammar D, Anderson G, Jorgensen F, Peterson PA, Rask L. Class I1 genes of the human major histocompatibility complex. Comparisons of the DQ and DX a and b genes. J Biol Chem 1987: 262 8767-77.

128. Horn GT, Bugawan TL, Long CM, Erlich HA. Allelic sequence variation of the HLA-DQ loci: relationship to serology and to insulin-dependent diabetes susceptibility. Proc. Natl. Acad. Sci. USA 1988: 85: 6012-6.

129. Fenske TS, and Baxter-Lowe LA. Two novel HLA- DQEl*06 alleles reveal additional heterogeneity of HLA- DQwl. Tissue Antigens 1992: 40: 49-52.

130. Lee BS, Bell JI, Rust NA, McDevitt HO. Structural and functional variability among DQ b alleles of DR2 sub- types. Immunogenetics 1987: 26: 85-91.

131. Tsukamoto K, Yasunami M, Kimura A, Inoko H, Ando A, Hirose T, Inayama S , Sasazuki T. DQwl beta gene from HLA-DR2-Dwl2 consists of six exons and expresses multiple DQw 1 beta polypeptides through alternative splicing. Immunogenetics 1987: 25: 343-346.

132. Singal DP, Qiu X, Sood SK. Molecular analysis of novel HLA-DR2.DQwl haplotypes in Asian Indians. Tissue Antigens 1992: 40: 10&-107.

133. Hurley CK, Gregersen P, Steiner N, Bell J, Hartzman R, Nepom G, Silver J, Johnson AH. Polymorphism of the HLA-D region in American blacks. A DR3 haplotype generated by recombination. J. Immunology 1988: 140:

134. Lee KW, Johnson AH, Hurley CK. Two divergent routes of evolution gave rise to the DRwl3 haplotypes. J. Immu- nology 1988: 145: 3119-25.

135. Scharf SJ, Freidmann A, Steinman L, Brautbar C, Erlich HA. Specific HLA-DQB and HLA-DRBI alleles confer susceptibility to pemphigus vulgaris lpublished erratum appears in Proc Natl Acad Sci U S A 1989 86:10023]. Proc. Natl. Acad. Sci. USA 1989: 86: 6215-9.

136. Fronek Z, Timmerman LA, McDevitt HO. A rare HLA DQP allele sequenced from patients with systemic lupus erythematosus. Human Immunology I991 : 30: 77-84.

137. Meyer CG, Spauke D. DQBI*MDvR-I: a synonymous mutation at DQBl codon 57. Tissue Antigens in press.

138. Aldener A, Olerup 0. Characterisation of a novel DQBl (DQBl*O609) allele by PCR amplification with sequence- specific primers (PCR-SSP) and nucleotide sequencing. Tissue Antigens 1993: 42: 536-538.

3 17-322.

751 5-7528.

885-92.

16

Nomenclature for factors of the HLA system, 1994

allele from the Santa Cruz Islands, Solomon Islands. Im- munogenerics 1993: 38: 79.

159. Ogawa K, Itho H, Nakajyo S, Kobayashi K, Sekiguchi S, Koshizaka T, Taguchi M. Onishi H, Kobayahi S, lnoko H. A novel HLA-DPBI allele, DPB1*3601 (DPBI’KT). Tissue Antigens 1994: in press.

160. Meyer CG, Schnittger L, Begovich AB, Erlich HA, Horstmann RD. DPBI*WA4 - an additional HLA class I1 allele identified in West Africa. Tissue Antigens 1992:

161. Mitsunaga S, Kuwata S, Tokunaga K, Uchikawa C, Tak- ahashi K, Akaza T, Mitomi Y, Juji T. Family study on HLA-DPBl polymorphism: Linkage analysis with HLA- D R l D Q and Two “New” alleles. Human Immunology

162. Mizuki N, Ohno S, Sugimura K, Seki T, Mizuki N, Ishioka M, Inoko H. Identification of a new HLA-DPB1 allele detected by PCR-RFLP and its nucleotide sequence determination by direct sequencing after PCR amplifi- cation. Tissue Antigens 1993: 41: 259-262.

163. Easteal S, Croft L. A new HLA-DPBI allele from the Santa Cruz Islands, Solomon Islands. Immunogenetics 1993: 38: 78.

164. de Vries N, Meijerink JPP, Tijssen H, Deemas M, Mensink EJBM, van de Putte LBA. A novel HLA-DPBI allele (DPBI*NM) in a Dutch Caucasian healthy control. Tissue Antigens 1993: 41: 255-258.

165. Mitsunaga S, Shinno K, Maruya E, Tokunaga K, Saji H. Nucleotide sequence of a novel DPBl allele, DPB1*4701. Human Immunology 1993: 37: 198-200.

166. Koshizaka T, Taguchi M, Onishi H, Kobayashi S , Inoko H. A new HLA-DPBI allele, DPBI*SUT. Tissue Antigens

167. Schnittger L, Aldrich C, Spauke D, Erlich HA, Meyer C. DPBI*SIOI - a novel DPB1*0402-related allele in West Africa affects DPBl genotyping. Tissue Antigens

168. Argyris EG, Gibson CF, Kamoun M, Zmijewski CM, Williams TM, Monos DS. Identification of a new HLA- DPBl allele (DPBI*5101) by oligotyping and nucleotide sequencing. Immttnogenetics 1994: in press.

169. Kaneshige T, Kinoshita T, Hashimoto M. Direct sequenc- ing analysis of a novel DPBl allele (DPBI*5101), from a heterozygous dot blot analysis. Tissue Anrigens 1994: in press.

170. Kelly AP, Monaco JJ, Cho S, Trowsdale J. A new human HLA class 11-related locus, DM. Nature 1991: 353: 571-573.

171. Sanderson F, Powis SH, Kelly AP, Trowsdale J. Limited polymorphism in HLA-DM does not involve the peptide binding groove. Imrnunogenetics 1993: 39: 56-58.

172. Carrington M, Harding A. Sequence analysis of two novel HLA-DMA alleles. Immunogenetics 1994: in press.

173. Carrington M, Yeager M, Mann D. Characterization of HLA-DMB polymorphism. Immunogenetics 1993: 38: 446-449.

174. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R. A gene in the human major histocompatibility complex class 11 region controlling the class I antigen presentation pathway. Nature 1991: 348: 744-747.

175. Trowsdale J, Hanson I. Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class I1 region of the MHC related to the ’ABC’ superfamily of transporters. Nnitir~ 1991: 348: 741-744.

176. Jackson DG, Capra JD. TAP- I Alleles in insulin-deprnd- ant diabetes mellitus: A newly defined centromeric botind- x y of disease susceptibility. Proc Notl. Acari. Si. USA 1993: 90: 11079-1 1083.

177. Powis SH. Mockridge I , Kelly A. Kerr LA. Glynne R.

40: 98-99.

1992: 34: 203-211.

1994: 43: 50-53.

139. Titus-Trachtenberg EA. Bugawan TL, Erlich HA. Identifi- cation of a novel DQBl allele (*0609) segregating in an Ashkenashi Jewish family: Implications for DQBl typing systems. Tissue Antigens 1994: in press.

140. Hall MA, Lanchbury JS, Lee JS, Welsh KI, Ciclitira PJ. HLA-DQ1 Second-domain polymorphisms may explain increased Trans-associated risk in Celiac disease and Der- matitis Herpetifomis. Human Immunology 1993: 38: 284-292.

141. Karr RW, Gregersen PK, Obata F, Goldberg D, Maccari J, Alber C, Silver J. Analysis of DR beta and DQ beta chain cDNA clones from a DR7 haplotype. J. Immunology 1988: 137: 2886-90.

142. Giorda R, Turco E, Trucco M. Full length b chain cDNAs of DQw9 and DQw8 molecules encode proteins that differ only at amino acid 57. Immunogenetics 1991: 33: 404- 408.

143. Cucca F, Frau F, Lampis R, Cao A, De Virgiliis S , Congia M. HLA-DQB 1 *0305 and -DQB I *0304 alleles among Sardinians: Evolutionary and practical implications for oligotyping. Human Immunology 1994: 40: in press.

144. Cucca F, Muntoni F, Lampis R, Frau F, Cao A, De Virgilis S, Congia M. A novel HLA-DQBl allele: evidence for gene conversion event promoted by c-like sequence at DQB locus. Tissue Antigens 1993: 41: 263-266.

145. Guethlein LA, Bias WB, Schmeckpeper BJ. New DP se- quences: Three DPAl and one DPBI. Tissue Antigens 1993: 41: 269-272.

136. Bugawan TL, Horn GT, Long CM, Mickelson E, Hansen JA, Ferrara GB, Angelini G, Erlich HA. Analysis of HLA- DP allelic sequence polymorphism using the in vitro enzy- matic DNA amplification of DP-alpha and DP-beta loci. J. Immunology 1988: 141: 4024-30.

147. Lee JS, Sartoris S, Briata P. Choi E, Cullen C, Lepaslier D, Yunis I . Sequence polymorphism of HLA-DP beta chains. Immunogenetics 1989: 29: 346-9.

148. Korioth F. Hartung K, Deicher H, Frey J. A new HLA- DPBl allele from a patient with systemic lupus ery- thematosus. Tissue Anligens 1992: 39: 216-219.

149. Meyer CG. Schnittger L. A silent mutation in HLA- DPBl*OIOl and its evolutionary implications. Human Im- intinology 1993: 38: 123-126.

150. Moonsamy PV, Aldrich CL, Petersdorf EW, Hill AVS. Begovich AB. Seven New DPBl alleles and their popula- tion distribution. Tissue Antigens 1994: 43: 248-251.

151. de Koster HS, Kenter MJH, D’Amaro J, Luiten RM. Schroeijers WEM, Giphart MJ, Termijtelen A. Positive correlation between oligonucleotide typing and T-cell rec- ognition of HLA-DP molecules. Imrnunogenetics 1991 : 31: 12-21.

152. Madsen HO, Ryder LP, Fugger L, 0dum N, Jakobsen BK, Svejgaard A. New DPBl alleles. Tissue Antigens 1992:

153. Savage DA, Middleton D, Trainor F, Taylor A, McKenna PG, Darke C. Frequency of HLA-DPBI alleles, including a novel DPBl sequence, in the Northern Ireland popula- tion. Human Immunology 1992: 33: 235-237.

154. Hessner MJ, and Baxter-Lowe LA. Characterisation of Novel HLA-DPB 1 alleles by oligotyping and nucleotide sequencing. Tissue Antigens 1992: 40: 261-763.

155. Dekker JW, Croft J, Easteal S. Nucleotide sequence of a novel HLA-DPB 1 allele. Irnr~i~mogerieric~s 1992: 36:

156. Mryer C. Spauke D, Schnittger L. MHC cI;iss I1 DPB1*16012 - convergent evolution at the DPBl locus. Tissiie ..lniiCms in press.

157. Exteal S. Croft L. Two new HLA-DPBI nlleles from Java. Indonesia. l tn~~i t r~iogme~ics 1993: 37: 47s.

153. Exreill S, Grooms A. Croft L. A second nrw HLA-DPB I

39: 102-103.

34 1-343.

17

Bodmer et al.

Gileadi U, Beck S, Trowsdale J. Polymorphism in a second ABC transporter gene located within the class I 1 region of the human major histocompatibility complex. Proc. Natl. Acad. Sci. U S A 1992: 89: 71463-1467.

178. Powis SH, Tonks S, Mockridge I, Kelly A, Kerr BJG, Trowsdale J. Alleles and haplotypes of the MHC-encoded ABC transporters TAP I and TAP2. Immunogenetics 1993:

179. Kimura A, Sasazuki T. Polymorphism in the 5’ flanking region of the HLA-DQAI gene and its relation to the DR-DQ haplotype. In: K. Tsuji, M. Aizawa and T. Sasa-

37: 373-380.

zuki ed. HLA 1991, Oxford: Oxford University Press, 1992: 382-385.

Address: Dr Julia G. Bodrner Imperial Cancer Research Fund 44 Lincoln’s Inn Fields London WC2A 3PX United Kingdom Tel. 44-71-269-3395 FAX 44-71-831-6786